263 related articles for article (PubMed ID: 24844912)
1. Computational algorithm-driven evaluation of monocytic myeloid-derived suppressor cell frequency for prediction of clinical outcomes.
Kitano S; Postow MA; Ziegler CG; Kuk D; Panageas KS; Cortez C; Rasalan T; Adamow M; Yuan J; Wong P; Altan-Bonnet G; Wolchok JD; Lesokhin AM
Cancer Immunol Res; 2014 Aug; 2(8):812-21. PubMed ID: 24844912
[TBL] [Abstract][Full Text] [Related]
2. Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab.
Meyer C; Cagnon L; Costa-Nunes CM; Baumgaertner P; Montandon N; Leyvraz L; Michielin O; Romano E; Speiser DE
Cancer Immunol Immunother; 2014 Mar; 63(3):247-57. PubMed ID: 24357148
[TBL] [Abstract][Full Text] [Related]
3. Ipilimumab treatment decreases monocytic MDSCs and increases CD8 effector memory T cells in long-term survivors with advanced melanoma.
de Coaña YP; Wolodarski M; Poschke I; Yoshimoto Y; Yang Y; Nyström M; Edbäck U; Brage SE; Lundqvist A; Masucci GV; Hansson J; Kiessling R
Oncotarget; 2017 Mar; 8(13):21539-21553. PubMed ID: 28423487
[TBL] [Abstract][Full Text] [Related]
4. Clinical and prognostic significance of CD14 (+) HLA-DR (-/low) myeloid-derived suppressor cells in patients with hepatocellular carcinoma received transarterial radioembolization with Yttrium-90.
Boral B; Ballı HT; Sözütok S; Pehlivan UA; Aikimbaev K
Scand J Immunol; 2022 Mar; 95(3):e13132. PubMed ID: 34936119
[TBL] [Abstract][Full Text] [Related]
5. Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign.
Poschke I; Mougiakakos D; Hansson J; Masucci GV; Kiessling R
Cancer Res; 2010 Jun; 70(11):4335-45. PubMed ID: 20484028
[TBL] [Abstract][Full Text] [Related]
6. Clinical Significance of Circulating CD33+CD11b+HLA-DR- Myeloid Cells in Patients with Stage IV Melanoma Treated with Ipilimumab.
Sade-Feldman M; Kanterman J; Klieger Y; Ish-Shalom E; Olga M; Saragovi A; Shtainberg H; Lotem M; Baniyash M
Clin Cancer Res; 2016 Dec; 22(23):5661-5672. PubMed ID: 27178742
[TBL] [Abstract][Full Text] [Related]
7. Tumor-induced CD14+HLA-DR (-/low) myeloid-derived suppressor cells correlate with tumor progression and outcome of therapy in multiple myeloma patients.
Wang Z; Zhang L; Wang H; Xiong S; Li Y; Tao Q; Xiao W; Qin H; Wang Y; Zhai Z
Cancer Immunol Immunother; 2015 Mar; 64(3):389-99. PubMed ID: 25548095
[TBL] [Abstract][Full Text] [Related]
8. Myeloid-derived suppressor cells impair the quality of dendritic cell vaccines.
Poschke I; Mao Y; Adamson L; Salazar-Onfray F; Masucci G; Kiessling R
Cancer Immunol Immunother; 2012 Jun; 61(6):827-38. PubMed ID: 22080405
[TBL] [Abstract][Full Text] [Related]
9. Long term impact of CTLA4 blockade immunotherapy on regulatory and effector immune responses in patients with melanoma.
Retseck J; Nasr A; Lin Y; Lin H; Mendiratta P; Butterfield LH; Tarhini AA
J Transl Med; 2018 Jul; 16(1):184. PubMed ID: 29973204
[TBL] [Abstract][Full Text] [Related]
10. Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab.
Tarhini AA; Edington H; Butterfield LH; Lin Y; Shuai Y; Tawbi H; Sander C; Yin Y; Holtzman M; Johnson J; Rao UN; Kirkwood JM
PLoS One; 2014; 9(2):e87705. PubMed ID: 24498358
[TBL] [Abstract][Full Text] [Related]
11. Myeloid-derived suppressor cells are associated with disease progression and decreased overall survival in advanced-stage melanoma patients.
Jordan KR; Amaria RN; Ramirez O; Callihan EB; Gao D; Borakove M; Manthey E; Borges VF; McCarter MD
Cancer Immunol Immunother; 2013 Nov; 62(11):1711-22. PubMed ID: 24072401
[TBL] [Abstract][Full Text] [Related]
12. Myeloid Cells and Related Chronic Inflammatory Factors as Novel Predictive Markers in Melanoma Treatment with Ipilimumab.
Gebhardt C; Sevko A; Jiang H; Lichtenberger R; Reith M; Tarnanidis K; Holland-Letz T; Umansky L; Beckhove P; Sucker A; Schadendorf D; Utikal J; Umansky V
Clin Cancer Res; 2015 Dec; 21(24):5453-9. PubMed ID: 26289067
[TBL] [Abstract][Full Text] [Related]
13. CLL-cells induce IDOhi CD14+HLA-DRlo myeloid-derived suppressor cells that inhibit T-cell responses and promote TRegs.
Jitschin R; Braun M; Büttner M; Dettmer-Wilde K; Bricks J; Berger J; Eckart MJ; Krause SW; Oefner PJ; Le Blanc K; Mackensen A; Mougiakakos D
Blood; 2014 Jul; 124(5):750-60. PubMed ID: 24850760
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of plasmacytoid dendritic cells and myeloid-derived suppressor cells in melanoma.
Chevolet I; Speeckaert R; Schreuer M; Neyns B; Krysko O; Bachert C; Van Gele M; van Geel N; Brochez L
J Transl Med; 2015 Jan; 13():9. PubMed ID: 25592374
[TBL] [Abstract][Full Text] [Related]
15. Effect of Immune Checkpoint Blockade on Myeloid-Derived Suppressor Cell Populations in Patients With Melanoma.
Sun SH; Benner B; Savardekar H; Lapurga G; Good L; Abood D; Nagle E; Duggan M; Stiff A; DiVincenzo MJ; Suarez-Kelly LP; Campbell A; Yu L; Wesolowski R; Howard H; Shah H; Kendra K; Carson WE
Front Immunol; 2021; 12():740890. PubMed ID: 34712230
[TBL] [Abstract][Full Text] [Related]
16. Ipilimumab treatment results in an early decrease in the frequency of circulating granulocytic myeloid-derived suppressor cells as well as their Arginase1 production.
Pico de Coaña Y; Poschke I; Gentilcore G; Mao Y; Nyström M; Hansson J; Masucci GV; Kiessling R
Cancer Immunol Res; 2013 Sep; 1(3):158-62. PubMed ID: 24777678
[TBL] [Abstract][Full Text] [Related]
17. Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab.
Weber J; Gibney G; Kudchadkar R; Yu B; Cheng P; Martinez AJ; Kroeger J; Richards A; McCormick L; Moberg V; Cronin H; Zhao X; Schell M; Chen YA
Cancer Immunol Res; 2016 Apr; 4(4):345-53. PubMed ID: 26873574
[TBL] [Abstract][Full Text] [Related]
18. Targeting myeloid-derived suppressor cells using all-trans retinoic acid in melanoma patients treated with Ipilimumab.
Tobin RP; Jordan KR; Robinson WA; Davis D; Borges VF; Gonzalez R; Lewis KD; McCarter MD
Int Immunopharmacol; 2018 Oct; 63():282-291. PubMed ID: 30121453
[TBL] [Abstract][Full Text] [Related]
19. Myeloid-derived suppressor cell measurements in fresh and cryopreserved blood samples.
Kotsakis A; Harasymczuk M; Schilling B; Georgoulias V; Argiris A; Whiteside TL
J Immunol Methods; 2012 Jul; 381(1-2):14-22. PubMed ID: 22522114
[TBL] [Abstract][Full Text] [Related]
20. The proportion of circulating CD45RO
Tietze JK; Angelova D; Heppt MV; Reinholz M; Murphy WJ; Spannagl M; Ruzicka T; Berking C
Eur J Cancer; 2017 Apr; 75():268-279. PubMed ID: 28242504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
